CIBRA Capital Ltd Purchases New Holdings in SpringWorks Therapeutics (NASDAQ:SWTX)

CIBRA Capital Ltd purchased a new position in SpringWorks Therapeutics (NASDAQ:SWTX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 37,543 shares of the company's stock, valued at approximately $1,657,000. SpringWorks Therapeutics comprises about 0.6% of CIBRA Capital Ltd's portfolio, making the stock its 18th biggest holding. CIBRA Capital Ltd owned approximately 0.05% of SpringWorks Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in SWTX. Schroder Investment Management Group grew its position in shares of SpringWorks Therapeutics by 93.6% in the fourth quarter. Schroder Investment Management Group now owns 168,209 shares of the company's stock valued at $6,113,000 after purchasing an additional 81,314 shares during the period. Vanguard Group Inc. grew its position in shares of SpringWorks Therapeutics by 6.6% in the fourth quarter. Vanguard Group Inc. now owns 7,158,871 shares of the company's stock valued at $258,650,000 after purchasing an additional 445,593 shares during the period. BIT Capital GmbH grew its position in shares of SpringWorks Therapeutics by 18.7% in the fourth quarter. BIT Capital GmbH now owns 53,539 shares of the company's stock valued at $1,934,000 after purchasing an additional 8,429 shares during the period. Platinum Investment Management Ltd. purchased a new stake in shares of SpringWorks Therapeutics in the fourth quarter valued at $1,694,000. Finally, Swiss National Bank grew its position in SpringWorks Therapeutics by 7.4% during the fourth quarter. Swiss National Bank now owns 116,800 shares of the company's stock valued at $4,220,000 after acquiring an additional 8,000 shares during the period.

SpringWorks Therapeutics Price Performance

Shares of NASDAQ SWTX remained flat at $46.99 on Friday. SpringWorks Therapeutics has a 1 year low of $28.21 and a 1 year high of $62.00. The stock has a 50-day moving average price of $46.58 and a 200 day moving average price of $44.50. The firm has a market capitalization of $3.54 billion, a PE ratio of -13.78 and a beta of 0.68.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 51.10% and a negative net margin of 115.60%. The company had revenue of $49.09 million during the quarter, compared to analysts' expectations of $64.19 million. On average, equities analysts anticipate that SpringWorks Therapeutics will post -2.05 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SWTX shares. HC Wainwright reissued a "neutral" rating and set a $47.00 price target (down previously from $74.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, April 30th. Guggenheim reissued a "neutral" rating and set a $47.00 price target on shares of SpringWorks Therapeutics in a research report on Monday, May 12th. Wedbush reissued a "neutral" rating and set a $47.00 price target (down previously from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Barclays reissued an "equal weight" rating and set a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Finally, Cowen downgraded SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, SpringWorks Therapeutics currently has a consensus rating of "Hold" and an average target price of $52.57.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.